Synergistic cytotoxicity of pyrazoloacridine with doxorubicin, etoposide, and topotecan in drug-resistant tumor cells.
D000166:Acridines / Q000008:administration & dosage*; D000362:Agar / Q000737:chemistry; D000951:Antigens, Neoplasm; D000970:Antineoplastic Agents / Q000494:pharmacology; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002384:Catalysis; D045744:Cell Line, Tumor; D002467:Cell Nucleus / Q000378:metabolism; D002986:Clinical Trials as Topic; D004247:DNA / Q000378:metabolism; D004264:DNA Topoisomerases, Type I / Q000378:metabolism; D004250:DNA Topoisomerases, Type II / Q000378:metabolism; D004278:DNA, Superhelical; D004268:DNA-Binding Proteins; D004305:Dose-Response Relationship, Drug; D004317:Doxorubicin / Q000008:administration & dosage*; D004357:Drug Synergism; D005047:Etoposide / Q000008:administration & dosage*; D006801:Humans; D020128:Inhibitory Concentration 50; D011720:Pyrazoles / Q000008:administration & dosage*; D019772:Topotecan / Q000008:administration & dosage*
D000166:Acridines; D000951:Antigens, Neoplasm; D000970:Antineoplastic Agents; D004278:DNA, Superhelical; D004268:DNA-Binding Proteins; D011720:Pyrazoles; D005047:Etoposide; D019772:Topotecan; D004317:Doxorubicin; D000362:Agar; D004247:DNA; D004264:DNA Topoisomerases, Type I; D004250:DNA Topoisomerases, Type II; C064541:NSC 366140